The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Classic psychedelics produce altered states of consciousness that individuals often interpret as meaningful experiences. Across a number of human studies, when the participant-rated intensity of the overall drug effects are statistically controlled for, certain subjective effects predict therapeutic and other desirable outcomes. Underlying neurobiological mechanisms are likely necessary but not sufficient to confer full and enduring beneficial effects. We propose that the subjective effects of psychedelics are necessary for their enduring beneficial effects and that these subjective effects account for the majority of their benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“because psychedelics are not only beneficial in populations suffering from psychopathologies, but also for those without, enhancing social and cognitive skills such as empathy and creativity, but also general well-being (18, 112).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [112]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These associations could reflect target engagement (ketamine-induced glutamate release), leading to dissociative effects, a subsequent elicitation of synaptogenesis and resultant antidepressant response 28,56,57 .”
From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, in this state, individuals may more readily engage with their cognitive beliefs and emotional states with enhanced detachment and decentration, potentially leading to therapeutic outcomes [42, 43].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [43]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Given the dose-response relationship between the glutamate surge, synaptogenesis and antidepressant response following ketamine administration 28,56,57 , it is possible that the relationship between derealization and increased SV2A density observed here is mediated by glutamate release.”
From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [57]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Self-citationNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Self-citationCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Self-citationPsychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Self-citation
Cited by
Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O’Donnell, K., Owens, L. T., Podrebarac, S., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.2096 · Cited by 711
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · Neuron · doi:10.1016/j.neuron.2021.06.008 · Cited by 626
Psychedelics promote plasticity by directly binding to BDNF receptor TrkB
Moliner, R., Girych, M., Brunello, C. A., Kovaleva, V., Biojone, C., Enkavi, G., Antenucci, L., Kot, E. F., Goncharuk, S. A., Kaurinkoski, K., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01316-5 · Cited by 478
Hesselgrave, N., Troppoli, T. A., Wulff, A. B., Cole, A. B., & Thompson, S. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022489118 · Cited by 378
“There is a widespread expectation that these psilocybininduced alterations in consciousness are essential to the antidepressant response (2, 9, 10); however, this hypothesis has never been tested clinically or preclinically.”
Backgroundvon Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., et al. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101809 · Cited by 354
The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects
Olson, D. E. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00192 · Cited by 329
Towards an understanding of psychedelic-induced neuroplasticity
Calder, A. E., & Hasler, G. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01389-z · Cited by 313
“Furthermore, mystical experiences, emotional breakthroughs, and insights correlate significantly with positive longterm effects, independently from the overall intensity of drug effects [155, 159].”
BackgroundPsychedelics, mystical experience, and therapeutic efficacy: a systematic review
Ko, K., Knight, G., Rucker, J. J., & Cleare, A. J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.917199 · Cited by 306
“Mystical experience has often been identified as a phenomenon related to acute psychedelic experience (14), which is defined as a range of subjective effects including visual alteration, acute anxiety, and insightfulness, among others (21), when administered at high dosage (27, 28).”
BackgroundInfluentialThe neural basis of psychedelic action
Kwan, A. C., Olson, D. E., Preller, K. H., & Roth, B. L. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01177-4 · Cited by 302
de Vos, C. M. H., Mason, N. L., & Kuypers, K. P. C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.724606 · Cited by 269
Default Mode Network Modulation by Psychedelics: A Systematic Review
Gattuso, J. J., Perkins, D., Ruffell, S., Lawrence, A. J., Hoyer, D., Jacobson, L. H., Timmermann, C., Castle, D., Rossell, S. L., Downey, L. A., et al. (2023) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac074 · Cited by 256
“However, it is important to note that challenging experiences may also be conducive of positive therapeutic outcomes (Yaden and Griffiths, 2020).”
BackgroundMethodInfluentialTherapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression
Murphy, R., Kettner, H., Zeifman, R., Giribaldi, B., Kartner, L., Martell, J., Read, T., Murphy-Beiner, A., Baker-Jones, M., Nutt, D., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.788155 · Cited by 250
Aday, J. S., Heifets, B. D., Pratscher, S. D., Bradley, E., Rosen, R., & Woolley, J. D. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06123-7 · Cited by 237
“1 3 researchers argue (Yaden and Griffiths 2020), the subjective effects produced by psychedelics (particularly mystical states) themselves drive therapeutic benefit.”
de la Fuente Revenga, M., Zhu, B., Guevara, C. A., Naler, L. B., Saunders, J. M., Zhou, Z., Toneatti, R., Sierra, S., Wolstenholme, J. T., Beardsley, P. M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109836 · Cited by 224
“One of the still-open questions in the field is whether the subjective effects of psychedelics are necessary or complementary for their post-acute clinically relevant outcomes in patients with severe psychiatric disorders such as depression (Olson, 2020; Yaden and Griffiths, 2020).”
Aday, J. S., Davis, A. K., Mitzkovitz, C. M., Bloesch, E. K., & Davoli, C. C. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00014 · Cited by 224
Psychedelic-inspired drug discovery using an engineered biosensor
Dong, C., Ly, C., Dunlap, L. E., Vargas, M. V., Sun, J., Hwang, I.-W., Azinfar, A., Oh, W. C., Wetsel, W. C., Olson, D. E., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.043 · Cited by 213
Psychedelics and Other Psychoplastogens for Treating Mental Illness.
Vargas, M. V., Meyer, R., Avanes, A. A., Rus, M., & Olson, D. E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727117 · Cited by 166
Watts, R., Kettner, H., Geerts, D., Gandy, S., Kartner, L., Mertens, L., Timmermann, C., Nour, M. M., Kaelen, M., Nutt, D., et al. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06187-5 · Cited by 164
“This result adds to a large body of findings showing that acute subjective effects induced by psychedelics are fundamental to the therapeutic efficacy induced by psychedelics (MacLean et al. 2011; Roseman et al. 2017; Schenberg 2018; Yaden and Griffiths 2020).”
BackgroundResultInfluentialTimmermann, C., Bauer, P. R., Gosseries, O., Vanhaudenhuyse, A., Vollenweider, F., Laureys, S., Singer, T., Antonova, E., & Lutz, A. (2023) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2022.11.006 · Cited by 150
Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis
Hinkle, J. T., Graziosi, M., Nayak, S. M., & Yaden, D. B. (2024) · JAMA psychiatry · doi:10.1001/jamapsychiatry.2024.2546 · Cited by 156
Self-citationA non-hallucinogenic LSD analog with therapeutic potential for mood disorders
Lewis, V., Bonniwell, E. M., Lanham, J. K., Ghaffari, A., Sheshbaradaran, H., Cao, A. B., Calkins, M. M., Bautista-Carro, M. A., Arsenault, E., Telfer, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112203 · Cited by 164
“18,19 However, it may be possible to decouple the hallucinogenic effects of psychedelic drugs from their therapeutic effects.”
BackgroundHistory repeating: guidelines to address common problems in psychedelic science
van Elk, M., & Fried, E. I. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231198466 · Cited by 137
“107,121 Connecting the dots Validity threats are problematic when they occur in isolation, but valid inferences become exponentially more difficult when validity threats interact with each other.”
BackgroundBiochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity
Olson, D. E. (2022) · Biochemistry · doi:10.1021/acs.biochem.1c00812 · Cited by 162
5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines
Cameron, L. P., Patel, S. D., Vargas, M. V., Barragan, E. V., Saeger, H. N., Warren, H. T., Chow, W. L., Gray, J. A., & Olson, D. E. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00718 · Cited by 135
Treatment with psychedelics is psychotherapy: beyond reductionism
Gründer, G., Brand, M., Mertens, L. J., Jungaberle, H., Kärtner, L., Scharf, D., Spangemacher, M., & Wolff, M. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00363-2 · Cited by 129
Reckweg, J. T., Uthaug, M. V., Szabó, A., Davis, A. K., Lancelotta, R., Mason, N. L., & Ramaekers, J. G. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15587 · Cited by 134
“Potential mechanisms underlying positive mental health changes induced by psychedelics have been attributed to both the psychological psychedelic experience (Yaden & Griffiths, 2021) as well as the underlying neurophysiological mechanisms (Olson, 2021).”
BackgroundErkizia-Santamaría, I., Alles-Pascual, R., Horrillo, I., Meana, J. J., & Ortega, J. E. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113612 · Cited by 119
McCulloch, D. E.-W., Grzywacz, M. Z., Madsen, M. K., Jensen, P. S., Ozenne, B., Armand, S., Knudsen, G. M., Fisher, P. M., & Stenbæk, D. S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.841648 · Cited by 125
Expectancy in placebo-controlled trials of psychedelics: if so, so what?
Butler, M., Jelen, L., & Rucker, J. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06221-6 · Cited by 100
“It is certainly an open question to the extent of how much the subjective effects themselves are necessary for improvement; however, given what we currently know about psychedelics and the integral role of supportive psychological therapy, the burden of proof probably lies with those who argue that the therapeutic eff…”
BackgroundDoes Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?
Kočárová, R., Horáček, J., & Carhart-Harris, R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.661233 · Cited by 96
Beyond the 5-HT2AReceptor: Classic and Nonclassic Targets in Psychedelic Drug Action
Cameron, L. P., Benetatos, J., Lewis, V., Bonniwell, E. M., Jaster, A. M., Moliner, R., Ċastrén, E., McCorvy, J. D., Palner, M., & Aguilar‐Valles, A. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.1384-23.2023 · Cited by 109
Brennan, W., & Belser, A. B. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.866018 · Cited by 90
“, 2021)—and thereby the need for supportive therapy (Yakowicz, 2021)—the potential efficacy of this approach remains speculative (Yaden and Griffiths, 2020; Olson, 2021).”
BackgroundPerez, N., Langlest, F., Mallet, L., De Pieri, M., Sentissi, O., Thorens, G., Seragnoli, F., Zullino, D., Kirschner, M., Kaiser, S., et al. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.07.011 · Cited by 88
“…acknowledge that part of the very large effect size observed in our dose-response meta-analysis could also be attributed to factors such as the intensity of the psychedelic experience induced by relevant doses of psilocybin and the supportive psychotherapeutic setting ( Yaden and Griffiths, 2021 ).”
Bender, D., & Hellerstein, D. J. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06049-6 · Cited by 88
“The importance of the “mystical experience” in therapeutic outcomes continues to be debated (Olson 2021; Yaden and Griffiths 2021).”
BackgroundPsychedelics, Sociality, and Human Evolution
Rodríguez Arce, J. M., & Winkelman, M. J. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.729425 · Cited by 86
Psychedelics and Neural Plasticity: Therapeutic Implications
Grieco, S. F., Castrén, E., Knudsen, G. M., Kwan, A. C., Olson, D. E., Zuo, Y., Holmes, T. C., & Xu, X. (2022) · The Journal of Neuroscience · doi:10.1523/jneurosci.1121-22.2022 · Cited by 82
“While the subjective effects induced by psychedelics may offer some distinct benefits to patients (Yaden and Griffiths, 2020), there are potential pitfalls to psychedelic-assisted psychotherapy.”
Neural Mechanisms and Psychology of Psychedelic Ego Dissolution
Stoliker, D., Egan, G. F., Friston, K. J., & Razi, A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000508 · Cited by 102
Psychedelic perceptions: mental health service user attitudes to psilocybin therapy
Corrigan, K., Haran, M., McCandliss, C., McManus, R., Cleary, S., Trant, R., Kelly, Y., Ledden, K., Rush, G., O’Keane, V., et al. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02668-2 · Cited by 84
Imaging the effect of ketamine on synaptic density (SV2A) in the living brain
Holmes, S. E., Finnema, S. J., Naganawa, M., DellaGioia, N., Holden, D., Fowles, K., Davis, M., Ropchan, J., Emory, P., Ye, Y., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01465-2 · Cited by 78
“While one line of thought is that ketamine’s dissociative effects mediate the therapeutic response [57], the observation that increasing the dose beyond 0.”
BackgroundKozłowska, U., Nichols, C. D., Wiatr, K., & Figiel, M. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15509 · Cited by 89
“The “hallucinogenic” effects of psychedelics have been proposed to be directly associated with their therapeutic potential in psychedelic- assisted psychotherapeutical approach as the subjective peak intensity has a high correlation with therapeutic efficacy (Yaden & Griffiths, 2021).”
BackgroundSekssaoui, M., Bockaert, J., Marin, P., & Bécamel, C. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01794-6 · Cited by 89
Levin, A. W., Lancelotta, R., Sepeda, N. D., Gukasyan, N., Nayak, S., Wagener, T. L., Barrett, F. S., Griffiths, R. R., & Davis, A. K. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300501 · Cited by 82
Critical Period Plasticity as a Framework for Psychedelic-Assisted Psychotherapy
Lepow, L., Morishita, H., & Yehuda, R. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.710004 · Cited by 84
Tulver, K., Kaup, K., Laukkonen, R., & Aru, J. (2023) · Consciousness and Cognition · doi:10.1016/j.concog.2023.103494 · Cited by 94
Therapeutic mechanisms of psychedelics and entactogens
Heifets, B. D., & Olson, D. E. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01666-5 · Cited by 79
“The extent to which accompanying subjective effects are required is debated [43, 44], however all models in this framework rest on an assumption that long-term changes in behavior (e.g., therapeutic outcomes in humans) are the result of drug-induced plasticity that strengthen and/or weaken adaptive…”
BackgroundAn Integrated theory of false insights and beliefs under psychedelics
McGovern, H. T., Grimmer, H. J., Doss, M. K., Hutchinson, B. T., Timmermann, C., Lyon, A., Corlett, P. R., & Laukkonen, R. (2024) · Communications Psychology · doi:10.1038/s44271-024-00120-6 · Cited by 81
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
“While, it is generally accepted that the quality of the subjective experience, dependent on the optimization of set and setting (context) is a critical component of the therapeutic mechanism of action of psychedelic therapy (87, 174), some propose that the subjective effects may not be necessary to produce long-lastin…”
BackgroundSweeney, M. M., Nayak, S. M., Hurwitz, E. S., Mitchell, L. N., Swift, T. C., & Griffiths, R. R. (2022) · PLoS ONE · doi:10.1371/journal.pone.0271926 · Cited by 70
Self-citationWeiss, F., Magnesa, A., Gambini, M., Gurrieri, R., Annuzzi, E., Elefante, C., Perugi, G., & Marazziti, D. (2025) · Brain Sciences · doi:10.3390/brainsci15020117 · Cited by 74
“Some authors (“phenomenists”) maintain that, without these effects, no benefit occurs, being the psychedelic experience itself the core of therapeutic action [131].”
A unified model of ketamine’s dissociative and psychedelic properties
Marguilho, M., Figueiredo, I., & Castro-Rodrigues, P. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221140011 · Cited by 75
“…and cellular-level stimulation of neuroplasticity should be dependent on dose, not therapeutic relationship – and several authors have suggested that although these molecular mechanisms surely make a relevant contribution, they are not sufficient for long-lasting change (Yaden and Griffiths, 2021).”
BackgroundPsychedelic‐inspired approaches for treating neurodegenerative disorders
Saeger, H. N., & Olson, D. E. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15544 · Cited by 74
“…effects of drugs like ketamine and serotonergic psychedelics might not be necessary for their sustained beneficial effects on neuroplasticity and behavior (Cameron & Olson, 2022; Olson, 2020; Peters & Olson, 2021), though this remains a subject of intense debate (Yaden & Griffiths, 2020).”
BackgroundClinically relevant acute subjective effects of psychedelics beyond mystical experience
Yaden, D. B., Goldy, S. P., Weiss, B., & Griffiths, R. R. (2024) · Nature Reviews Psychology · doi:10.1038/s44159-024-00345-6 · Cited by 69
“…receptor occupancy and signalling, indexed using positron emission tomography, have been observed to covary with acute subjective intensity in humans (assessed via self-report Likert-scale ratings and correlated with acute subjective experience such as mystical-type experience 41 ) ( β = 0.34) 49 .”
InfluentialSelf-citationPsychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry
Aday, J. S., Barnett, B. S., Grossman, D., Murnane, K. S., Nichols, C. D., & Hendricks, P. S. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0013 · Cited by 67
“95 Much of these issues have not yet been resolved, in part because there can be up to a multiyear differential between a patent application and a final notice of issuance or rejection.”
Barker, S. A. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06065-0 · Cited by 58
“There is, however, conflicting evidence and opinion in this regard (Yaden and Griffiths, 2021).”
BackgroundResultToward Synergies of Ketamine and Psychotherapy
Mathai, D. S., Mora, V., & Garcia‐Romeu, A. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.868103 · Cited by 73
Shahar, O., Botvinnik, A., Esh-Zuntz, N., Brownstien, M., Wolf, R., Lotan, A., Wolf, G., Lerer, B., & Lifschytz, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214148 · Cited by 65
“A significant discussion is under way in the resurgent psychedelics field as to whether short-term subjective effects are needed for the therapeutic potential of psychedelics to be achieved (Olson, 2021; Yaden and Griffiths, 2021).”
BackgroundThe Emerging Field of Psychedelic Psychotherapy
Barber, G., & Aaronson, S. T. (2022) · Current Psychiatry Reports · doi:10.1007/s11920-022-01363-y · Cited by 68
Kopra, E. I., Ferris, J., WINSTOCK, A. R., Kuypers, K. P. C., Young, A. H., & Rucker, J. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231158245 · Cited by 68
“*p < 0.002. moderate–high doses, aimed to induce ‘peak’ or ‘mystical-type’ experiences and/or emotional breakthrough, that have been found to predict symptomatic improvement (Davis et al., 2020; Goodwin et al., 2022b; Ko et al., 2022; Yaden and Griffiths, 2020).”
BackgroundInfluentialPattern breaking: a complex systems approach to psychedelic medicine
Hipólito, I., Mago, J., Rosas, F. E., & Carhart-Harris, R. L. (2023) · Neuroscience of Consciousness · doi:10.1093/nc/niad017 · Cited by 78
“This suggests that the subjective effects of psychedelics may be crucial for the maintenance of therapeutic outcomes (Yaden and Griffiths 2020, Lutkajtis 2021).”
Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity
Glazer, J. E., Murray, C. H., Nusslock, R., Lee, R., & de Wit, H. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01479-y · Cited by 61
“…with psychedelic drugs: Some argue that the strong cognitive and emotional states observed with high doses of LSD and psilocybin are essential for the bene fi cial clinical outcome [79] while others [80] argue that the antidepressant effects may be dissociable from the perceptual experience.”
Aqil, M., & Roseman, L. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109300 · Cited by 68
“experiences as a key driver of the therapeutic benefits of psychedelics (Griffiths et al., 2016; Barrett and Griffiths, 2017; Roseman et al., 2018; Yaden and Griffiths, 2020).”
BackgroundOn the need for metaphysics in psychedelic therapy and research
Sjöstedt-Hughes, P. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1128589 · Cited by 66
“…main seeds: First, there is compelling evidence that psychedelic-induced metaphysical experiences per se are a mechanism of positive psychological benefit (Roseman et al., 2018; Mollaahmetoglu et al., 2021; Rothberg et al., 2021; Yaden and Griffiths, 2021; Ko et al., 2022; McCulloch et al., 2022).”
BackgroundInfluentialPsychedelic-induced mystical experiences: An interdisciplinary discussion and critique
Mosurinjohn, S. C., Roseman, L., & Girn, M. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1077311 · Cited by 72
Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics
Jaster, A. M., & González‐Maeso, J. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02274-x · Cited by 61
“…there is strong consensus that the acute subjective effects of psychedelics are mediated via the 5-HT 2A receptor, but the question remains whether 5-HT 2A receptor activation is also responsible for the potential therapeutic effects seen after the drug is eliminated from the system [229 – 233].”
Leger, R. F., & Unterwald, E. M. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211044688 · Cited by 63
Neuroinflammation and neuroprogression in depression: Effects of alternative drug treatments
Richardson, B., MacPherson, A., & Bambico, F. R. (2022) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2022.100554 · Cited by 66
“The quality of a psychedelic experience is important in one’s perception of the experience and thus affects the efficacy of treatment (Yaden and Griffiths, 2021).”
BackgroundResultEffective Connectivity of Functionally Anticorrelated Networks Under Lysergic Acid Diethylamide
Stoliker, D., Novelli, L., Vollenweider, F. X., Egan, G. F., Preller, K. H., & Razi, A. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.07.013 · Cited by 60
“Their mind-altering effects, which are undergoing translation into modern clinical therapies, may constitute a crucial component of their therapeutic efficacy (6,7).”
Agin-Liebes, G., Ekman, E., Anderson, B., Malloy, M., Haas, A., & Woolley, J. (2024) · Journal of Humanistic Psychology · doi:10.1177/00221678211022949 · Cited by 51
“While some researchers have challenged the notion that the subjective, psychological effects are key drivers of clinical improvements (Olson, 2021), an accumulating number of studies indicate their importance (Yaden & Griffiths, 2021).”
BackgroundYaden, D. B., Berghella, A. P., Regier, P. S., Garcia‐Romeu, A., Johnson, M. W., & Hendricks, P. S. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103380 · Cited by 55
Self-citationWolf, G., Singh, S., Blakolmer, K., Lerer, L. B., Lifschytz, T., Heresco‐Levy, U., Lotan, A., & Lerer, B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01832-z · Cited by 52
“It is widely held that the trip, occurring in the context of carefully monitored set and setting, is the key therapeutic component of the treatment [164].”
BackgroundRoméo, B., Kervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Bezo, A., Piolino, P., & Benyamina, A. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106086 · Cited by 67
Psychological and physiological effects of extended DMT
Luan, L., Eckernäs, E., Ashton, M., Rosas, F. E., Uthaug, M. V., Bartha, A., Jagger, S., Perai, K. G., Gomes, L., Nutt, D., et al. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231196877 · Cited by 66
“In the future, an approach tailored to the PK characteristics of the individual may thus be highly valuable to induce acute subjective effects that have been found to predict improvements in mental health outcomes in psy-chedelic experiences (Yaden and Griffiths, 2020).”
BackgroundStoliker, D., Novelli, L., Vollenweider, F. X., Egan, G. F., Preller, K. H., & Razi, A. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.01.002 · Cited by 52
Psilocybin Facilitates Fear Extinction: Importance of Dose, Context, and Serotonin Receptors
Woodburn, S. C., Levitt, C. M., Koester, A., & Kwan, A. C. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00279 · Cited by 57
Kałużna, A., Schlosser, M., Craste, E. G., Stroud, J., & Cooke, J. E. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00199 · Cited by 62
“In terms of the current psychedelic debate, the present piece of research is relevant to the question of the therapeutic importance of psychedelic-induced subjective effects (Olson, 2021; Yaden & Grif fi ths, 2021).”
The costs and benefits of psychedelics on cognition and mood
Sayalı, C., & Barrett, F. S. (2023) · Neuron · doi:10.1016/j.neuron.2022.12.031 · Cited by 48
Borkel, L. F., Rojas‐Hernández, J., Henríquez‐Hernández, L. A., Santana, Á., & Hernández, D. J. Q. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2295997 · Cited by 56
Mindfulness meditation and psychedelics: potential synergies and commonalities
Holas, P., & Kamińska, J. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00551-8 · Cited by 43
“Consequently, in this state, individuals may more readily engage with their cognitive beliefs and emotional states with enhanced detachment and decen-tration, potentially leading to therapeutic outcomes [42, 43].”
BackgroundThe frontiers of new psychedelic therapies: A survey of sociological themes and issues
Andrews, T., & Wright, K. (2022) · Sociology Compass · doi:10.1111/soc4.12959 · Cited by 48
Peterson, A. H., Largent, E. A., Lynch, H. F., Karlawish, J. H., & Sisti, D. A. (2022) · AJOB Neuroscience · doi:10.1080/21507740.2022.2148771 · Cited by 42
Effects of DMT on mental health outcomes in healthy volunteers
Timmermann, C., Zeifman, R. J., Erritzøe, D., Nutt, D., & Carhart-Harris, R. L. (2024) · Scientific Reports · doi:10.1038/s41598-024-53363-y · Cited by 55
“These include: (1) the short-duration of action associated with DMT administration compared with other psychedelics, as it is reasonable to assume that a longer experience is required for therapeutic benefits in certain difficult-to-treat clinical populations 66 .”
BackgroundMethodYu, Z., Burback, L., Winkler, O., Xu, L., Dennett, L., Vermetten, E. H. G. J. M., Greenshaw, A. J., Li, X., Milne, M., Wang, F., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1386321 · Cited by 50
“Yaden further emphasizes the value of other subjective effects, such as profound insights and emotional breakthroughs, in the potentially therapeutic effects of psychedelics (40).”
BackgroundOrłowski, P., Ruban, A., Szczypiński, J., Hobot, J., Bielecki, M., & Bola, M. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221089034 · Cited by 41
“Indirect effect of subjective aspects of psychedelic experiences To what extent acute subjective effects are necessary to observe lasting psychological changes induced by psychedelics is one of the key research questions in the psychedelics research field (Olson, 2021; Yaden and Griffiths, 2021).”
BackgroundResultWolff, M., Evens, R., Mertens, L. J., Schmidt, C., Beck, J. L., Rutrecht, H. M., Cherniak, A. D., Gründer, G., & Jungaberle, H. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241249698 · Cited by 41
“For example, psychedelic-occasioned peak experiences, including mystical-type experiences (Johnson et al., 2019; Yaden and Griffiths, 2021) and the closely related phenomenon of oceanic boundlessness (Dittrich, 1998; Majić et al., 2015) typically involve all hallmarks of resource-activating…”
BackgroundEngineering Safer Psychedelics for Treating Addiction
Peters, J., & Olson, D. E. (2021) · Neuroscience Insights · doi:10.1177/26331055211033847 · Cited by 45
Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia
Glynos, N. G., Pierce, J. M., Davis, A. K., McAfee, J., & Boehnke, K. F. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2021.2022817 · Cited by 45
Distinctive But Not Exceptional: The Risks of Psychedelic Ethical Exceptionalism
Cheung, K., Earp, B. D., Patch, K., & Yaden, D. B. (2025) · The American Journal of Bioethics · doi:10.1080/15265161.2024.2433421 · Cited by 40
“…inhibitors (SSRIs), to choose a familiar example, are typically taken long-term and do not induce the highly salient alterations in subjective experience characteristic of classic psychedelics (Griffiths et al. 2006, 2011; Schmid et al. 2021; Yaden and Griffiths 2021; Andersen et al. 2021).”
Self-citationPsilocybin history, action and reaction: A narrative clinical review
Sharma, P., Nguyen, Q. A., Matthews, S. J., Carpenter, E., Matthews, D. B., Patten, C. A., & Hammond, C. J. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231190858 · Cited by 44
“It is also suggested that although neurobiological mechanisms may explain some of the therapeutic effects of psilocybin, subjective experiences mediate these effects in humans (Yaden and Griffiths, 2020).”
BackgroundPsychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential
Allen, J., Dames, S., Foldi, C. J., & Shultz, S. R. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02360-0 · Cited by 47
“It could be that the hallucinogenic effects of psychedelics are essential for maximizing bene fi ts [269, 270].”
The Potential Role of Psychedelic Drugs in Mental Health Care of the Future
Gründer, G., & Jungaberle, H. (2021) · Pharmacopsychiatry · doi:10.1055/a-1486-7386 · Cited by 42
“The sustainability of psychedelic effects may be influenced by pharmacological and non-pharmacological factors such as the quality of the psychedelic experience and sociocultural factors that help to sustain beneficial attitudes and health behaviors in the individual [24, 25].”
BackgroundMoral Psychopharmacology Needs Moral Inquiry: The Case of Psychedelics
Langlitz, N., Dyck, E., Scheidegger, M., & Repantis, D. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.680064 · Cited by 41
“The subjective experience shaped by set and setting might not just be epiphenomenal but causally related to the drugs’ therapeutic effects (8).”
BackgroundReconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine
Mathai, D. S., Nayak, S. M., Yaden, D. B., & Garcia‐Romeu, A. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06324-8 · Cited by 40
“This appears to be the case for other psychedelic treatments under investigation such as psilocybin-assisted interventions, where therapeutic outcomes for anxiety, mood, and substance use disorders have shown significant association with qualities of the acute drug experience, such as mysticaltype effects, broadly def…”
BackgroundSelf-citationA framework for assessment of adverse events occurring in psychedelic-assisted therapies
Palitsky, R., Kaplan, D. M., Perna, J., Bosshardt, Z., Maples‐Keller, J. L., Levin-Aspenson, H. F., Zarrabi, A. J., Peacock, C., Mletzko, T., Rothbaum, B. O., et al. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241265756 · Cited by 48
Role of Psychedelics in Treatment-Resistant Depression
Kamal, S., Jha, M. K., & Radhakrishnan, R. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.004 · Cited by 38
A Brief Historical Overview of Psychedelic Research
Geyer, M. A. (2023) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2023.11.003 · Cited by 53
Breathwork-induced psychedelic experiences modulate neural dynamics
Lewis-Healey, E., Tagliazucchi, E., Canales‐Johnson, A., & Bekinschtein, T. A. (2024) · Cerebral Cortex · doi:10.1093/cercor/bhae347 · Cited by 40
The Potential of Psychedelics for End of Life and Palliative Care
Yaden, D. B., Nayak, S. M., Gukasyan, N., Anderson, B. T., & Griffiths, R. R. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_278 · Cited by 39
Self-citationEthical Issues Regarding Nonsubjective Psychedelics as Standard of Care
Yaden, D. B., Earp, B. D., & Griffiths, R. R. (2022) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s096318012200007x · Cited by 36
“” 2 According to this contrary view, certain cognitive and affective shifts from the subjective effects of psychedelics account for a large degree of the size and longevity of their beneficial effects.”
Self-citationMcMillan, R. M., & Fernandez, A. V. (2022) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674221139962 · Cited by 38
“Rather, patients’ subjective experiences seem to play an important causal role – some even argue that the subjective effects of psychedelics account for the majority of their therapeutic benefit (Yaden and Griffiths, 2021).”
BackgroundInfluentialDoss, M. K., de Wit, H., & Gallo, D. A. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105188 · Cited by 41
Metadata
- Authors
- Yaden, D. B., & Griffiths, R. R.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Griffiths, Roland R.
- Venue
- ACS Pharmacology & Translational Science
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-12-10
- Volume
- 4
- Issue
- 2
- Pages
- 568-572
- ISSN
- 2575-9108 (ISSN-L)
- PMC
- PMC8033615
- OpenAlex
- W3113263685
- Cited by
- 541
- References
- 28
- Citations by year
- 2026: 81 · 2025: 125 · 2024: 105 · 2023: 98 · 2022: 92 · 2021: 36 · 2020: 2
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- ACS Pharmacology & Translational Science (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Steven and Alexandra Cohen Foundation
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
- Keywords
- psychedelics, subjective effects, treatment outcomes, altered states of consciousness, meaningful experiences, subjective experience, neurobiological mechanisms, psychedelic therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.